Comparative Pharmacology
Head-to-head clinical analysis: BYETTA versus PRANDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYETTA versus PRANDIN.
BYETTA vs PRANDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
Repaglinide stimulates insulin secretion from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
5 mcg subcutaneously twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month if tolerated.
0.5–4 mg orally 0–30 minutes before meals, typically 2–4 times daily. Maximum single dose: 4 mg. Maximum total daily dose: 16 mg.
None Documented
None Documented
Terminal elimination half-life 2.4 hours; provides clinical duration of action supporting twice-daily dosing.
Terminal elimination half-life: 1.0-1.5 hours. Clinically, due to rapid elimination, repaglinide requires dosing before each meal to control postprandial glucose.
Primarily renal; intact drug eliminated in urine (approximately 80% of the dose). Minor biliary/fecal excretion accounts for <10%.
Primarily hepatic metabolism via CYP2C8 and CYP3A4; metabolites excreted in bile (90%) and urine (10%). Less than 0.1% excreted unchanged in urine.
Category C
Category C
Antidiabetic
Antidiabetic